A way round the 'real difficulties' of malaria sporozoite vaccine development?
Vaccines against the sporozoite stages of malaria, based on circumsporozoite (CS) protein epitopes, have had poor results in clinical trials. It has recently been suggested that attention should be switched to looking for new sporozoite, or hepatioc-stage proteins from which to develop vaccines. Here Francesco Sinigaglia and Richard Pink argue the case for reconsidering CS proteins as vaccines candidates.
Central Research Units, F. Hoffmann-La Roche Ltd, CH-4002 Basel, Switzerland.
F
F
Sinigaglia
J R
JR
Pink